Project Grant R43HL176348
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $313K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
- This federal Project Grant award of $598,636, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports the development of the EMULAATE platform by Spheric Bio Inc. The EMULAATE technology aims to address the mismatch between standard left atrial appendage occlusion (LAAO) devices and patient anatomy by enabling the assembly of personalized, soft implants directly inside the patient's body through a minimally-invasive procedure. This could...
- This $323,230 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a multi-channel radiofrequency and pulsed field energy source generator for cardiac ablation procedures. The award recipient, Sirona Medical Technologies, Inc., is developing a novel catheter device and customizable energy generator to improve the safety and precision of cardiac ablation treatments. Key product features include...
- The federal Project Grant award, valued at $413,595, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of a "Magnetic Rotational Platform for Coronary Lesions" by Unandup, LLC, a technology firm in St. Louis, Missouri. The project aims to create an innovative medical device technology that leverages magnetic fields to improve the treatment of severe coronary artery...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- This $499,103 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Alleviant Medical, Inc. in two key efforts: Implementing high-volume manufacturing capabilities and establishing production readiness for the ALV1 system, a novel transcatheter approach to relieve left atrial pressure in heart failure patients without requiring a cardiac implant. Executing reimbursement and marketing initiatives to...
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- This Project Grant award of $232,500.00 from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), aims to validate the effectiveness of a novel non-invasive approach for localizing ventricular tachycardia (VT) substrates. The PACE-VT (Personalized Automated VT Circuit and Exit Localization) methodology combines detailed structural data from CT scans with functional data from ECGs to enhance the precision of non-invasive VT mapping. This...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...